Newly-released Intravenous Iron Drugs market analysis report by Future Market Insights shows that global sales of the Intravenous Iron Drugs Market in 2021 were held at USD 2.6 billion. With 8.5%, the projected market growth from 2022 to 2032 is expected to be higher than the historical growth.
The Intravenous Iron Drugs Market is projected to witness an absolute dollar opportunity of USD 3.5 billion. The prevalence of chronic kidney disease (CKD), Inflammatory Bowel Disease (IBD), and cancer have increased the demand for intravenous iron medicines for the treatment of subsequent Iron Deficiency Anaemia.
| Attribute | Details |
|---|---|
| Global Intravenous Iron Drugs Market (2022) | USD 2.8 billion |
| Global Intravenous Iron Drugs Market (2032) | USD 6.3 billion |
| Global Intravenous Iron Drugs Market CAGR (2022 to 2032) | 8.5% |
| USA Intravenous Iron Drugs Market (2022) | USD 922.7 million |
| Key Companies Profiled | Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; Shield Therapeutics Plc; AbbVie Inc.; Nippon Shinyaku Co. Ltd. |
As per the Intravenous Iron Drugs market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Intravenous Iron Drugs Market increased at around 8.1% CAGR, wherein, the region North America held a significant share in the global market.
Iron is a component of haemoglobin, which transports oxygen in the blood and also allows for the creation of red blood cells. Anaemia is a diagnosed condition in which an individual is lacking in the body's iron needs.
Anaemia symptoms include weariness and loss of energy, unusually quick heartbeat when exercising, difficulties concentrating, pale skin and dizziness, sleeplessness, and cramping.
According to a recent survey done by the Vitamin and Mineral Nutrition Information System (VMNIS), around 40% of mothers and children in poor nations are anaemic. As a result, the market is expected to grow at a CAGR of 8.5% over the next ten years.
Anaemia is one of the most frequent blood illnesses nowadays. Anaemia affects an estimated 3 million people in the United States, according to the National Heart, Lung, and Blood Institute.
The rising incidence of target illnesses such as rheumatoid arthritis, autoimmune diseases, renal issues, cancer, liver disorders, thyroid diseases, and inflammatory bowel disease is a significant factor driving the expansion of the intravenous iron medication market.
As per National Kidney Foundation, the two primary causes of CKD are diabetes and hypertension. Also, according to the report, the chronic renal disease affects approximately 10% of the worldwide population, with over 2 million people needing dialysis on a daily basis.
The bulk of all these people is often observed in nations such as Italy, the United States, Germany, Japan, and Brazil.
A significant number of people who have the disease are unaware of it until severe symptoms appear. The frequency of chronic kidney disease is expected to rise in developing economies such as India and China, implying an increase in the elderly population in the future years.
With the increasing incidence of these disorders, there is a greater demand for intravenous iron medicines.
One of the biggest disadvantages of oral iron medications is the possibility of significant side effects. Digestive issues such as stomach pains, constipation, lack of appetite, nausea, and vomiting are common side effects of oral iron medications.
Convulsions, shallow or quick breathing, exhaustion or weakness, fatigue, pale complexion, and bluish skin or fingernails can all result from an overdose of oral iron medications.
Intravenous iron medications, on the other hand, have been demonstrated to promote iron intake by the body, allowing Erythropoiesis-stimulating Agents (ESAs) to act more effectively in lowering anemic conditions.
Other benefits of intravenous iron medications include heart health preservation and the potential to be utilized by dialysis patients, particularly those undergoing hemodialysis. These negative effects are thus expected to assist the changeover to intravenous iron medications, boosting their use during the projection period.
The market in Asia Pacific is expected to swell at a significant pace of 8.6% from 2022 to 2032. This may be ascribed to the availability of prominent players in the Asia Pacific, as well as the strengthening of healthcare infrastructure with the growing government efforts. Furthermore, the prevalence of IDA in rising economies such as China and India has aided industry expansion.
Besides, the market in Europe is anticipated to increase significantly throughout the forecast year as a result of the growing research and commercialization of new products, the acceptance of advanced medications, and the region's rising incidence of malignancy.
The United States dominated the North American Intravenous Iron Drugs Market, which is expected to reach USD 2.2 billion by 2032 and will increase at a CAGR of 9.3% CAGR during the forecast period. The reimbursement and technological advancement facilities are advantageous factors for market growth in the United States.
The growing geriatric population is a key driver of market expansion in the country. According to USA Census Bureau projections, the number of Americans aged 65 and up is expected to grow from 52 million in 2018 to nearly 95 million by 2060. Furthermore, the share of people aged 65 and up is expected to rise from 16% to 23%.
Its dominance is also due to the region's rising rates of cancer, chronic renal disease, and gastrointestinal ailments. Furthermore, an increase in awareness of women's health and a surge in the frequency of celiac disease are the other factors boosting the market in the country.
The market for intravenous iron drugs in the United Kingdom stood at USD 115 million in 2021. The market in the country is projected to swell at a CAGR of 8.2% during the forecast period to reach a valuation of USD 278 million by 2032. The market in the country is expected to register an absolute dollar opportunity of USD 151 million from 2022 to 2032.
The market in Japan is likely to expand with an absolute dollar opportunity of USD 128 million from 2022 to 2032. The market in the country is expected to reach a valuation of USD 233 million by 2032 growing at a CAGR of 8.2% during the forecast period.
In South Korea, the market is projected to reach a valuation of USD 127 million by 2032, growing from USD 66 million in 2022. With an absolute dollar opportunity of USD 61 million, the market in the country is expected to register a CAGR of 6.7% during the forecast period.
In 2020, the market for intravenous iron drugs led the market for intravenous medicines for chronic kidney disease, accounting for 30% of the total in 2021.
This large market may be due to the fact that chronic kidney disease (CKD) and intravenous iron therapies are intensively used by CKD patients. IDA is a prevalent complication in CKD patients. It is uncommon in the early stages of renal illness; nevertheless, it happens as the disease progresses and kidney function declines.
Anaemia is caused by a decrease in the amount of Red Blood Cells (RBCs) in CKD patients. The growth in CKD cases has resulted in a large increase in the number of IDA patients. The conventional therapy for people with dialysis and non-dialysis-related CKD is intravenous iron. Dialysis is used to treat anaemia and end-stage renal failure.
Due to the increasing incidence of cancer and the consequent increase in the number of IDA cases, the market revenue through cancer application is expected to grow at the fastest CAGR throughout the projection period.
IDA affects a considerable proportion of cancer patients. Blood cancer, bone cancer, cervical cancer, colon cancer, and prostate cancer are all common cancers associated with anaemia. According to the NCBI, lung and breast cancers have the highest rate of anaemia among solid tumours.
Hematologic cancers, such as leukaemia, lymphoma, and multiple myeloma, create abnormal blood cells, which weaken the immune system and cause anaemia. Chemotherapy and radiation therapy are two cancer therapies that cause anaemia in individuals.
Some of the key players in the global Intravenous Iron Drugs market include Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; Shield Therapeutics Plc; AbbVie Inc., Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; and Shield Therapeutics Plc among others.
Some of the recent developments in the Intravenous Iron Drugs Market are:
Table 1: Global Market Value (US$ million), By Product Type, 2017 to 2021
Table 2: Global Market Value (US$ million), By Product Type, 2022 to 2032
Table 3: Global Market Value (US$ million), By Indication, 2017 to 2021
Table 4: Global Market Value (US$ million), By Indication, 2022 to 2032
Table 5: Global Market, By Region, 2017 to 2021
Table 6: Global Market, By Region, 2022 to 2032
Table 7: North America Market Value (US$ million), By Product Type, 2017 to 2021
Table 8: North America Market Value (US$ million), By Product Type, 2022 to 2032
Table 9: North America Market Value (US$ million), By Indication, 2017 to 2021
Table 10: North America Market Value (US$ million), By Indication, 2022 to 2032
Table 11: North America Market, By Country, 2017 to 2021
Table 12: North America Market, By Country, 2022 to 2032
Table 13: Latin America Market Value (US$ million), By Product Type, 2017 to 2021
Table 14: Latin America Market Value (US$ million), By Product Type, 2022 to 2032
Table 15: Latin America Market Value (US$ million), By Indication, 2017 to 2021
Table 16: Latin America Market Value (US$ million), By Indication, 2022 to 2032
Table 17: Latin America Market, By Country, 2017 to 2021
Table 18: Latin America Market, By Country, 2022 to 2032
Table 19: Europe Market Value (US$ million), By Product Type, 2017 to 2021
Table 20: Europe Market Value (US$ million), By Product Type, 2022 to 2032
Table 21: Europe Market Value (US$ million), By Indication, 2017 to 2021
Table 22: Europe Market Value (US$ million), By Indication, 2022 to 2032
Table 23: Europe Market, By Country, 2017 to 2021
Table 24: Europe Market, By Country, 2022 to 2032
Table 25: Asia Pacific Market Value (US$ million), By Product Type, 2017 to 2021
Table 26: Asia Pacific Market Value (US$ million), By Product Type, 2022 to 2032
Table 27: Asia Pacific Market Value (US$ million), By Indication, 2017 to 2021
Table 28: Asia Pacific Market Value (US$ million), By Indication, 2022 to 2032
Table 29: Asia Pacific Market, By Country, 2017 to 2021
Table 30: Asia Pacific Market, By Country, 2022 to 2032
Table 31: MEA Market Value (US$ million), By Product Type, 2017 to 2021
Table 32: MEA Market Value (US$ million), By Product Type, 2022 to 2032
Table 33: MEA Market Value (US$ million), By Indication, 2017 to 2021
Table 34: MEA Market Value (US$ million), By Indication, 2022 to 2032
Table 35: MEA Market, By Country, 2017 to 2021
Table 36: MEA Market, By Country, 2022 to 2032
Table 37: Global Market Incremental $ Opportunity, By Product Type, 2017 to 2021
Table 38: Global Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 39: Global Market Incremental $ Opportunity, By Region, 2022 to 2032
Table 40: North America Market Incremental $ Opportunity, By Product Type, 2017 to 2021
Table 41: North America Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 42: North America Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 43: Latin America Market Incremental $ Opportunity, By Product Type, 2017 to 2021
Table 44: Latin America Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 45: Latin America Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 46: Europe Market Incremental $ Opportunity, By Product Type, 2017 to 2021
Table 47: Europe Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 48: Europe Market Incremental $ Opportunity, By Country, 2022 - 2032
Table 49: Asia Pacific Market Incremental $ Opportunity, By Product Type, 2017 to 2021
Table 50: Asia Pacific Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 51: Asia Pacific Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 52: MEA Market Incremental $ Opportunity, By Product Type, 2017 to 2021
Table 53: MEA Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 54: MEA Market Incremental $ Opportunity, By Country, 2022 to 2032
Figure 1: Global Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032
Figure 2: Global Market Absolute $ Historical Gain (2017 to 2021) and Opportunity (2022 to 2032), US$ million
Figure 3: Global Market Share, By Product Type, 2022 to 2032
Figure 4: Global Market Y-o-Y Growth Projections, By Product Type - 2022 to 2032
Figure 5: Global Market Attractiveness Index, By Product Type - 2022 to 2032
Figure 6: Global Market Share, By Indication, 2022 to 2032
Figure 7: Global Market Y-o-Y Growth Projections, By Indication - 2022 to 2032
Figure 8: Global Market Attractiveness Index, By Indication - 2022 to 2032
Figure 9: Global Market Share, By Region, 2022 to 2032
Figure 10: Global Market Y-o-Y Growth Projections, By Region - 2022 to 2032
Figure 11: Global Market Attractiveness Index, By Region - 2022 to 2032
Figure 12: North America Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032
Figure 13: North America Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million
Figure 14: North America Market Share, By Product Type, 2022 to 2032
Figure 15: North America Market Y-o-Y Growth Projections, By Product Type - 2022 to 2032
Figure 16: North America Market Attractiveness Index, By Product Type - 2022 to 2032
Figure 17: North America Market Share, By Indication, 2022 to 2032
Figure 18: North America Market Y-o-Y Growth Projections, By Indication - 2022 to 2032
Figure 19: North America Market Attractiveness Index, By Indication - 2022 to 2032
Figure 20: North America Market Share, By Country, 2022 to 2032
Figure 21: North America Market Y-o-Y Growth Projections, By Country - 2022 to 2032
Figure 22: North America Market Attractiveness Index, By Country - 2022 to 2032
Figure 23: Latin America Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032
Figure 24: Latin America Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million
Figure 25: Latin America Market Share, By Product Type, 2022 to 2032
Figure 26: Latin America Market Y-o-Y Growth Projections, By Product Type - 2022 to 2032
Figure 27: Latin America Market Attractiveness Index, By Product Type - 2022 to 2032
Figure 28: Latin America Market Share, By Indication, 2022 to 2032
Figure 29: Latin America Market Y-o-Y Growth Projections, By Indication - 2022 to 2032
Figure 30: Latin America Market Attractiveness Index, By Indication - 2022 to 2032
Figure 31: Latin America Market Share, By Country, 2022 to 2032
Figure 32: Latin America Market Y-o-Y Growth Projections, By Country - 2022 to 2032
Figure 33: Latin America Market Attractiveness Index, By Country - 2022 to 2032
Figure 34: Europe Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032
Figure 35: Europe Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million
Figure 36: Europe Market Share, By Product Type, 2022 to 2032
Figure 37: Europe Market Y-o-Y Growth Projections, By Product Type - 2022 to 2032
Figure 38: Europe Market Attractiveness Index, By Product Type - 2022 to 2032
Figure 39: Europe Market Share, By Indication, 2022 to 2032
Figure 40: Europe Market Y-o-Y Growth Projections, By Indication - 2022 to 2032
Figure 41: Europe Market Attractiveness Index, By Indication - 2022 to 2032
Figure 42: Europe Market Share, By Country, 2022 to 2032
Figure 43: Europe Market Y-o-Y Growth Projections, By Country - 2022 to 2032
Figure 44: Europe Market Attractiveness Index, By Country - 2022 to 2032
Figure 45: MEA Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032
Figure 46: MEA Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million
Figure 47: MEA Market Share, By Product Type, 2022 to 2032
Figure 48: MEA Market Y-o-Y Growth Projections, By Product Type - 2022 to 2032
Figure 49: MEA Market Attractiveness Index, By Product Type - 2022 to 2032
Figure 50: MEA Market Share, By Indication, 2022 to 2032
Figure 51: MEA Market Y-o-Y Growth Projections, By Indication - 2022 to 2032
Figure 52: MEA Market Attractiveness Index, By Indication - 2022 to 2032
Figure 53: MEA Market Share, By Country, 2022 to 2032
Figure 54: MEA Market Y-o-Y Growth Projections, By Country - 2022 to 2032
Figure 55: MEA Market Attractiveness Index, By Country - 2022 to 2032
Figure 56: Asia Pacific Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032
Figure 57: Asia Pacific Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million
Figure 58: Asia Pacific Market Share, By Product Type, 2022 to 2032
Figure 59: Asia Pacific Market Y-o-Y Growth Projections, By Product Type - 2022 to 2032
Figure 60: Asia Pacific Market Attractiveness Index, By Product Type - 2022 to 2032
Figure 61: Asia Pacific Market Share, By Indication, 2022 to 2032
Figure 62: Asia Pacific Market Y-o-Y Growth Projections, By Indication - 2022 to 2032
Figure 63: Asia Pacific Market Attractiveness Index, By Indication - 2022 to 2032
Figure 64: Asia Pacific Market Share, By Country, 2022 to 2032
Figure 65: Asia Pacific Market Y-o-Y Growth Projections, By Country - 2022 to 2032
Figure 66: Asia Pacific Market Attractiveness Index, By Country - 2022 to 2032
Figure 67: USA Market Value (US$ million) and Forecast, 2022 to 2032
Figure 68: USA Market Share, By Product Type, 2021
Figure 69: USA Market Share, By Indication, 2021
Figure 70: Canada Market Value (US$ million) and Forecast, 2022 to 2032
Figure 71: Canada Market Share, By Product Type, 2021
Figure 72: Canada Market Share, By Indication, 2021
Figure 73: Brazil Market Value (US$ million) and Forecast, 2022 to 2032
Figure 74: Brazil Market Share, By Product Type, 2021
Figure 75: Brazil Market Share, By Indication, 2021
Figure 76: Mexico Market Value (US$ million) and Forecast, 2022 to 2032
Figure 77: Mexico Market Share, By Product Type, 2021
Figure 78: Mexico Market Share, By Indication, 2021
Figure 79: Germany Market Value (US$ million) and Forecast, 2022 to 2032
Figure 80: Germany Market Share, By Product Type, 2021
Figure 81: Germany Market Share, By Indication, 2021
Figure 82: The United Kingdom Market Value (US$ million) and Forecast, 2022 to 2032
Figure 83: The United Kingdom Market Share, By Product Type, 2021
Figure 84: The United Kingdom Market Share, By Indication, 2021
Figure 85: France Market Value (US$ million) and Forecast, 2022 to 2032
Figure 86: France Market Share, By Product Type, 2021
Figure 87: France Market Share, By Indication, 2021
Figure 88: Italy Market Value (US$ million) and Forecast, 2022 to 2032
Figure 89: Italy Market Share, By Product Type, 2021
Figure 90: Italy Market Share, By Indication, 2021
Figure 91: BENELUX Market Value (US$ million) and Forecast, 2022 to 2032
Figure 92: BENELUX Market Share, By Product Type, 2021
Figure 93: BENELUX Market Share, By Indication, 2021
Figure 94: Nordic Countries Market Value (US$ million) and Forecast, 2022 to 2032
Figure 95: Nordic Countries Market Share, By Product Type, 2021
Figure 96: Nordic Countries Market Share, By Indication, 2021
Figure 97: China Market Value (US$ million) and Forecast, 2022 to 2032
Figure 98: China Market Share, By Product Type, 2021
Figure 99: China Market Share, By Indication, 2021
Figure 100: Japan Market Value (US$ million) and Forecast, 2022 to 2032
Figure 101: Japan Market Share, By Product Type, 2021
Figure 102: Japan Market Share, By Indication, 2021
Figure 103: South Korea Market Value (US$ million) and Forecast, 2022 to 2032
Figure 104: South Korea Market Share, By Product Type, 2021
Figure 105: South Korea Market Share, By Indication, 2021
Figure 106: GCC Countries Market Value (US$ million) and Forecast, 2022 to 2032
Figure 107: GCC Countries Market Share, By Product Type, 2021
Figure 108: GCC Countries Market Share, By Indication, 2021
Figure 109: South Africa Market Value (US$ million) and Forecast, 2022 to 2032
Figure 110: South Africa Market Share, By Product Type, 2021
Figure 111: South Africa Market Share, By Indication, 2021
Figure 112: Turkey Market Value (US$ million) and Forecast, 2022 to 2032
Figure 113: Turkey Market Share, By Product Type, 2021
Figure 114: Turkey Market Share, By Indication, 2021
The global market is worth more than USD 2.6 billion at present.
The value of the Intravenous Iron Drugs Market is projected to increase at a CAGR of around 8.5% from 2022 to 2032.
The value of the Intravenous Iron Drugs Market increased at a CAGR of around 8.1% from 2017 to 2021.
The top 5 countries driving demand for the Intravenous Iron Drugs market are the USA, China, the United Kingdom, Japan, and South Korea.
The USA market for Intravenous Iron Drugs is projected to expand at a CAGR of around 9.3% from 2022 to 2032.
The key companies in intravenous iron drugs market are AMAG Pharmaceuticals, AbbVie Inc., Daiichi Sankyo Company Ltd., Sanofi, and Vifor Pharma Management Ltd.
Explore Similar Insights
Intravenous Iron Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
